Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. announced results from a Phase IIb/III clinical trial for CINQUIL (reslizumab) as a treatment for pediatric eosinophilic esophagitis.
San Francisco Business Times